pozelimab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
primate origin 5740 2096328-94-6

Description:

MoleculeDescription

Molfile

Synonyms:

  • pozelimab
  • pozelimab-bbfg
  • REGN3918
  • veopoz
Pozelimab-bbfg is a human, monoclonal immunoglobulin G4P (IgG4P) antibody directed against the terminal complement protein C5 that inhibits terminal complement activation by blocking cleavage of C5 into C5a (anaphylatoxin) and C5b, thereby blocking the formation of the membrane-attack complex (C5b-C9, a structure mediating cell lysis).
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
Aug. 18, 2023 FDA REGENERON PHARMACEUTICALS

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L04AJ11 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
IMMUNOSUPPRESSANTS
IMMUNOSUPPRESSANTS
Complement inhibitors
FDA EPC N0000175575 Complement Inhibitor
FDA MoA N0000175974 Complement Inhibitors

Related Drugs by ATC class:

L04AJ Complement inhibitors 10 drugs
avacopancrovalimab-akkzdanicopaneculizumabiptacopanpegcetacoplanravulizumabsutimlimabvilobelimabzilucoplan

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
CHAPLE disease indication 1279887007
Meningococcal infectious disease contraindication 23511006




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Complement C5 Secreted INHIBITOR Kd 9.72 DRUG LABEL DRUG LABEL

External reference:

IDSource
CHEBI:757505 CHEBI
CHEMBL4298086 ChEMBL_ID
C000731768 MESH_SUPPLEMENTAL_RECORD_UI
12900 IUPHAR_LIGAND_ID
DB15218 DRUGBANK_ID
4042758 VANDF
4042759 VANDF
C5139913 UMLSCUI
10945 INN_ID
370431 MMSL
41916 MMSL
d10098 MMSL
019529 NDDF
D11477 KEGG_DRUG
0JJ21K6L2I UNII
2663938 RXNORM

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
VEOPOZ HUMAN PRESCRIPTION DRUG LABEL 1 61755-014 INJECTION, SOLUTION 200 mg SUBCUTANEOUS BLA 29 sections